Cell cycle inhibitors for the treatment of NSCLC

Author： Shcherba Marina   Liang Yuanxin   Fernandes David   Perez-Soler Roman   Cheng Haiying  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.15, Iss.7, 2014-05, pp. : 991-1004

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC

By  

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-05 ,pp. : 3894-3900

Bentham Science Publishers

Access to resources Recommend Favorite

Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC)

By Blumenschein George  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1802-1811

Springer Publishing Company

Access to resources Recommend Favorite

Emerging cell-cycle inhibitors for pancreatic cancer therapy

By Bayraktar Soley  

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 4, 2012-12 ,pp. : 571-582

Informa Healthcare

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 67-73

Bentham Science Publishers

Access to resources Recommend Favorite